Clinical Trial to Treat Rectal Cancer Spares Major Surgery

Clinical trial to treat rectal cancer spares major surgery

A new treatment for earlier-stage rectal cancer could transform how patients are treated for the disease, according to a landmark clinical trial.

Bowel cancer patients spared major surgery after ‘life-changing’ trial

Around 80 per cent of patients were spared radical surgery following the trial treatment

Rectal cancer trial offers non-surgical treatment hope

Findings suggest that organ‑preserving treatment may be an option for those with early rectal cancer.

Clinical Trial Spares Rectal Cancer Surgery

Table of ContentsHow the STAR-TREC Rectal Cancer Surgery Trial Was CoordinatedThe Trial’s Design and Patient PopulationThe Key Results Behind This STAR-TREC Rectal Cancer Surgery TrialWhat Total Mesorectal Excision Traditionally RequiresWhat Researchers Are Saying About This STAR-TREC Rectal Cancer Surgery BreakthroughA “Smarter, Kinder” Radiotherapy ApproachWhy Longer-Term Follow-Up Still Matters for This STAR-TREC Rectal Cancer Surgery TrialWh…

Rectal cancer treatment spares surgery for most patients

Surgical treatment of rectal cancer often means complete removal of the rectum. Now, new trial results suggest a different approach that lets patients keep their rectum – along with significant quality-of-life benefits.

University of Birmingham-Led Trial Finds Rectum-Preserving Treatment Could Spare Many Rectal Cancer Patients Major Surgery

Open the article to view the coverage from EuropaWire.eu